Novo Nordisk Overview
Novo Nordisk A/S is a pharmaceutical company that specializes in diabetes care medications and devices. It produces insulin, GLP-1 analogs, obesity drugs, and biopharmaceuticals, as well as insulin pens, needles, and glucose monitoring devices. Digital Innovation Hubs in major health-tech ecosystems worldwide to accelerate digital progress in defeating chronic diseases. The Hubs will connect with local start-ups and organizations, co-create solutions, and amplify Novo Nordisk's purpose. The network spans globally, with Hubs already launched in China, UK, Germany, Brazil, and Israel.
Latest News
growth-positive
Novo Nordisk Bulks Up Its Obesity-Tied Portfolio With $5.2 Billion Buyout
Novo Nordisk has announced a significant acquisition, agreeing to pay up to $5.2 billion to acquire Akero Therapeutics. This acquisition is aimed at enhancing Novo Nordisks portfolio related to obesity and liver disease treatments. Akero Therapeutics is known for its experimental liver disease treatment, which aligns with Novo Nordisks strategic focus on expanding its offerings in the healthcare sector. This move is seen as growth-positive for Novo Nordisk, as it strengthens its position in the market and potentially opens up new avenues for revenue generation.
Acquisition
growth-positive
Sector Update: Health Care Stocks Advance Late Afternoon
The article discusses the rise in healthcare stocks, with the NYSE Health Care Index increasing by 0.3% late Thursday afternoon. The mention of NOVO-B.CO suggests a positive impact on the company as part of the broader healthcare sectors growth. The article is part of a premium news service, requiring a Silver or Gold subscription for full access. No specific details about NOVO-B.COs operations, partnerships, or financial activities are provided in the text.
growth-positive
TEVA Stock Up More Than 19% in a Month: Buy, Sell or Hold the Stock?
Teva Pharmaceutical Industries Limited has seen a 19.4% rise in its stock price over the past month, driven by its mixed second-quarter results announced on July 30. While the company missed sales estimates, it exceeded earnings expectations. The growth in sales of its branded drugs Austedo, Ajovy, and Uzedy has been a key factor, with Austedo sales projected to exceed $3 billion by 2030. Tevas partnership with Sanofi for the development of duvakitug, an anti-TL1A therapy, is also noteworthy. The company plans to advance its pipeline with new drug applications and further international launches.
Product StagePartners
growth-positive
Teva brings first generic GLP-1 to US market with Saxenda copycat approval
Teva Pharmaceutical has received FDA approval for its generic version of Saxenda, a glucagon-like peptide-1 receptor agonist (GLP-1RA) used for weight loss. This marks the first generic GLP-1RA approved for weight loss in the US. Despite the rise of next-generation drugs like Wegovy and Zepbound, which have dominated sales, Tevas generic could capture a significant patient share due to its lower cost. Analysts suggest that while the generic may not impact the sales of more effective drugs, it could expand access to GLP-1RAs for patients who do not require high-efficacy treatments. The GLP-1RA market is projected to grow significantly in the coming years.
FDA approved/pending approval
growth-positive
FDA Approves First-Ever Generic Weight-Loss Drug In A Blow To Novo Nordisk
The FDA has approved the first-ever generic weight-loss drug, a knockoff of Novo Nordisks Saxenda, developed by Teva Pharmaceutical. This approval marks a significant milestone for Teva, as it allows them to enter the weight-loss drug market with a generic version, potentially increasing their market share and revenue. The approval is seen as a setback for Novo Nordisk, which previously held a strong position in the market with Saxenda. The introduction of a generic alternative is expected to make weight-loss treatments more accessible and affordable for consumers.
FDA approved/pending approval
Team Members
3
Employees: 51-200
Web & Social Links
| Website | www.novonordisk.com/ |
Locations
Atir Yeda St 1, Kefar Sava, Israel
Novo Alle 1, 2880 Bagsværd, Denmark
Photos & Videos
No files yet
Novo Nordisk Business
Business models
—
Product stage
—
Employees
51-200
Sector
—Target Customer
—Core Technology
—Tags (3)
pharmaceuticalsinnovation-centerdiabetesNovo Nordisk Financials
—
Total funding
—
Capital raised
—
Last funding
—
Funding stage
—
Total rounds
—
Investors
Novo Nordisk Lifecycle
Novo Nordisk News
18 articles
growth-positive
Novo Nordisk Bulks Up Its Obesity-Tied Portfolio With $5.2 Billion Buyout
Novo Nordisk has announced a significant acquisition, agreeing to pay up to $5.2 billion to acquire Akero Therapeutics. This acquisition is aimed at enhancing Novo Nordisks portfolio related to obesity and liver disease treatments. Akero Therapeutics is known for its experimental liver disease treatment, which aligns with Novo Nordisks strategic focus on expanding its offerings in the healthcare sector. This move is seen as growth-positive for Novo Nordisk, as it strengthens its position in the market and potentially opens up new avenues for revenue generation.
Acquisition
growth-positive
Sector Update: Health Care Stocks Advance Late Afternoon
The article discusses the rise in healthcare stocks, with the NYSE Health Care Index increasing by 0.3% late Thursday afternoon. The mention of NOVO-B.CO suggests a positive impact on the company as part of the broader healthcare sectors growth. The article is part of a premium news service, requiring a Silver or Gold subscription for full access. No specific details about NOVO-B.COs operations, partnerships, or financial activities are provided in the text.
growth-positive
TEVA Stock Up More Than 19% in a Month: Buy, Sell or Hold the Stock?
Teva Pharmaceutical Industries Limited has seen a 19.4% rise in its stock price over the past month, driven by its mixed second-quarter results announced on July 30. While the company missed sales estimates, it exceeded earnings expectations. The growth in sales of its branded drugs Austedo, Ajovy, and Uzedy has been a key factor, with Austedo sales projected to exceed $3 billion by 2030. Tevas partnership with Sanofi for the development of duvakitug, an anti-TL1A therapy, is also noteworthy. The company plans to advance its pipeline with new drug applications and further international launches.
Product StagePartners
growth-positive
Teva brings first generic GLP-1 to US market with Saxenda copycat approval
Teva Pharmaceutical has received FDA approval for its generic version of Saxenda, a glucagon-like peptide-1 receptor agonist (GLP-1RA) used for weight loss. This marks the first generic GLP-1RA approved for weight loss in the US. Despite the rise of next-generation drugs like Wegovy and Zepbound, which have dominated sales, Tevas generic could capture a significant patient share due to its lower cost. Analysts suggest that while the generic may not impact the sales of more effective drugs, it could expand access to GLP-1RAs for patients who do not require high-efficacy treatments. The GLP-1RA market is projected to grow significantly in the coming years.
FDA approved/pending approval
growth-positive
FDA Approves First-Ever Generic Weight-Loss Drug In A Blow To Novo Nordisk
The FDA has approved the first-ever generic weight-loss drug, a knockoff of Novo Nordisks Saxenda, developed by Teva Pharmaceutical. This approval marks a significant milestone for Teva, as it allows them to enter the weight-loss drug market with a generic version, potentially increasing their market share and revenue. The approval is seen as a setback for Novo Nordisk, which previously held a strong position in the market with Saxenda. The introduction of a generic alternative is expected to make weight-loss treatments more accessible and affordable for consumers.
FDA approved/pending approval
growth-positive
Saudi Arabia Blood Glucose Device Market Trends and Company Analysis Report 2025-2033 Featuring Abbott Laboratories, Medtronic, Dexcom, Braun, DarioHealth, Sanofi, Bionime, and Novo Nordisk
The Saudi Arabia Blood Glucose Device Market is projected to grow significantly from US$ 143.96 million in 2024 to US$ 259.8 million by 2033, driven by a rising incidence of diabetes, increased health awareness, and government initiatives. Advances in Continuous Glucose Monitoring (CGM) systems and user-friendly glucometers are enhancing patient compliance. Key players in the market include Abbott Laboratories, Medtronic, and Dexcom Inc. The market is supported by urban centers like Riyadh and Jeddah, indicating strong potential in Saudi Arabia. Lifestyle issues such as lack of physical activity and high-calorie diets contribute to the high diabetes prevalence, prompting government campaigns for early detection and self-management.
growth-negative
Stocks to watch next week: BP, Diageo, Disney, Uber and WPP
BP is set to release its second-quarter results amid declining oil and gas prices, with analysts expecting earnings of $1.35 per share and $60 billion in revenue. The company is under pressure due to weak cash flow, rising net debt, and challenges in its transition to cleaner energy sources. Activist investor Elliott has raised concerns over BPs performance, particularly its lagging shareholder returns. Analysts predict a pre-tax profit of $4.6 billion, up from $4.2 billion in Q1, but still below past levels. BPs cash flow and net debt, forecasted to be $24.9 billion by Q1 2025, remain key issues.
growth-positive
Alcohol Use Disorder Market Report 2025-2035 Featuring Clearmind Medicine, Purdue Pharma, Psyence Biomedical, Eli Lilly and Co, Tempero Bio,, Nxera Pharma, Novo Nordisk, Adial, Alkermes, Lundbeck
The global alcohol use disorder market is experiencing significant growth due to the demand for innovative and personalized treatments, and the integration of digital health technologies. Companies like Adial Pharmaceuticals and Clearmind Medicine are at the forefront of these advancements. The market is expected to expand robustly from 2025 to 2035, driven by personalized medicine, new pharmacotherapies, and digital health technologies like telemedicine. Despite challenges such as high costs and stigma, the market shows potential for further growth. Strategic collaborations and partnerships are key to tapping into untapped revenue opportunities.
Product StagePartners
Markets Stay Relatively Calm as Fragile Ceasefire Deal Follows Missile Strikes
The article discusses recent geopolitical tensions between the United States and Iran, following US attacks on Iranian nuclear facilities and Irans retaliatory missile strikes on a US airbase in Qatar. Despite initial fears of escalating conflict, diplomatic efforts led to a ceasefire agreement between Israel and Iran, announced by President Donald Trump. This de-escalation reassured global markets, with oil prices dropping significantly and stock indices like the S&P 500, Nasdaq, and Dow Jones rising. The article also mentions Irans parliamentary vote to potentially close the Strait of Hormuz, a critical oil trade route, though such a move seems unlikely. Overall, the situation appears to be stabilizing, with investors responding positively to the developments.
growth-negative
Trending tickers: Boeing, Adobe, Exxon, Oracle and Novo Nordisk
Boeings shares fell 1.4% in pre-market trading following a fatal crash involving a Boeing 787-8 Dreamliner operated by Air India. This incident marks the first fatal accident involving a 787 since its entry into service in 2011. Despite the aircrafts strong safety record, Boeing has been working to restore its reputation after previous safety and quality control issues, particularly with its 737 MAX program. Analysts suggest the market reaction may be overdone given the 787s historical performance. Meanwhile, Adobes shares also fell after reporting earnings that did not meet investor expectations, although the company raised its full-year revenue and profit forecasts.
growth-positive
Charter to combine with Cox, Take-Two reports mixed Q4 results: Morning Buzz
Charter Communications (CHTR) is set to merge with Cox in a deal valuing Cox at an enterprise value of $34.5 billion. This merger is seen as a major positive for Charter, as indicated by Oppenheimers upgrade of the company to Outperform. The article also mentions other companies like Take-Two, Applied Materials, and Novo Nordisk, with various updates on their financial results and management changes. Additionally, the article touches on broader market trends, including consumer sentiment data, housing starts, and commodity prices. The merger between Charter and Cox is expected to have a significant impact on the telecommunications industry.
Acquired-by
growth-positive
eToro's Nasdaq debut, Exelixis outlook, Septerna–Novo deal
eToro has successfully made its public debut on the Nasdaq Composite, opening at $69.69, which is above its IPO price of $52. This marks a significant milestone for the trading platform, which had previously delayed its IPO plans. The debut is seen as growth-positive for the company. Additionally, Exelixis has reported strong first-quarter earnings and has raised its full-year revenue forecast, contributing to a rise in its share price. Septerna and Cytokinetics have both entered into significant deals with Novo Nordisk, valued at $2.2 billion each, focusing on obesity medications. These developments highlight key movements in the market, with partnerships and revenue forecasts being central themes.
Public Trading
Obesity Drugs Are a Potential $100 Billion Opportunity by 2030, Goldman Sachs Analysts Say
Weight-Loss Drug Frenzy Cements Novo Nordisk as Europe’s Most Valuable Company
growth-positive
Novo Nordisk Drugs Are Shaking Up Stock Markets Again
Novo Nordisk A/S, a Danish company, has seen its diabetes drugs, Ozempic and Wegovy, cause significant disruption in the stock market. The company recently halted a study on the impact of Ozempic on kidney failure due to early signs of effectiveness, causing shares of major kidney dialysis providers to plummet. The drugs, known as GLP-1s, have also impacted demand for food and beverage companies due to their appetite-suppressing effects. Despite this, Novo Nordisks stock has risen 43% this year, and other companies developing obesity treatments, like Eli Lilly & Co., have also seen gains.
CustomersPartners
growth-positive
Novo’s Blockbuster Ozempic Now Shows Kidney Promise, Hitting Rivals
Novo Nordisk A/Ss diabetes drug, Ozempic, has shown early effectiveness in a kidney-failure study, leading to a rise in Novos shares and a fall in shares of dialysis providers. An independent data monitoring committee recommended halting the study after an interim analysis met pre-set criteria for efficacy. The full results of the study are expected by the first half of 2024. Fresenius Medical Care AG & Co.’s shares plunged as much as 24% in Frankfurt, erasing over €2.5 billion ($2.7 billion) in market value. Baxter International Inc. and DaVita Inc. fell 7% and 15% respectively in early US trading.
CustomersPartners
Growth-Positive
How weight loss drugs could have chain reaction in 'food ecosystem'
Novo Nordisks weight loss drugs, Ozempic and Wegovy, are growing in popularity, with potential long-term implications for the food industry. Morgan Stanley Equity Research Analyst Pam Kaufman predicts a fivefold increase in drug use over the next 12 years, with about 7% of the population expected to be on the drugs by 2035. This could impact long-term demand for food consumption. The forecast is based on increasing insurance coverage, with the cost of the drugs expected to decrease over time.
CustomersExpand
growth-negative
Ozempic Maker Novo Drops After First Stock Split in a Decade
Shares of Danish drugmaker Novo Nordisk fell in the first trading session following a two-for-one stock split aimed at increasing the liquidity of the companys stock. The company, which makes weight-loss drugs Ozempic and Wegovy, saw its shares rise almost sevenfold since its last stock split in January 2014, driven by its leadership in the global market for obesity drugs. However, some analysts believe that the obesity revenue opportunity wont be as big as Novos current valuation implies.
Management ChangesPublic Trading
Novo Nordisk Team
Employee Info
| Employees (range) | 51-200 |
| Exact count | 126 |
| Team members | 3 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
Novo Nordisk Internal
Recent Updates
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-03-15 16:43:56.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-03-15 16:41:49.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-03-15 16:34:48.000000
Eran Levin
· eranl@sncentral.org · Automatic · 2025-02-06 12:41:36.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-03-15 16:44:43.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-03-15 15:45:08.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-03-15 16:51:13.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-03-15 16:59:36.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-03-15 16:40:04.000000
Eran Levin
· eranl@sncentral.org · Automatic · 2024-01-25 16:21:01.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-03-15 16:44:57.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-03-15 16:33:50.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-03-15 16:59:58.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-03-15 15:58:07.000000
Maor Perlov
· maor.perlov@sncentral.org · Automatic · 2023-03-15 16:59:36.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-03-15 15:45:08.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-03-15 16:46:02.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-03-15 15:58:07.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-03-15 15:44:52.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-03-15 16:43:39.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-03-15 16:38:11.000000
Eran Levin
· eranl@sncentral.org · Automatic · 2024-12-05 14:19:38.000000
Maor Perlov
· maor.perlov@sncentral.org · Automatic · 2023-03-15 16:59:36.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-03-15 16:43:56.000000
Maor Perlov
· maor.perlov@sncentral.org · Automatic · 2023-03-15 16:52:39.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-03-15 15:44:52.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-03-15 16:44:43.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-03-15 16:02:32.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-03-15 17:02:46.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-03-15 15:48:14.000000
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 71/100 |
| Missing | product stage, sector, business model, video or image, funding rounds, news, markets, not claimed |
| Creator | Maor Perlov |
| Creator email | maor.perlov@sncentral.org |
| Last update | 2023-03-15T00:00:00.000Z |
| Created | 2023-03-15T00:00:00.000Z |
| Status detail | Public on OMX on Oct, 1980;Public on NYSE on Sep, 1981; |